Headline News about Neurocrine Bioscienc
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
![](https://www.investors.com/wp-content/uploads/2023/07/Stock-royalcaribbean-cruiseship-02-adobe.jpg)
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp)
![](https://cdn.benzinga.com/files/images/story/2024/pharma-lab-worker-ai_13.png?width=1200&height=800&fit=crop)
![](https://www.chartmill.com/images/uploads/thumbnail_article_luc_kroeze_c1f44c837d.webp)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_3.png?width=1200&height=800&fit=crop)
Decoding 8 Analyst Evaluations For Neurocrine Biosciences
March 13, 2024
Via Benzinga
![](https://www.investors.com/wp-content/uploads/2017/05/IRU5.jpg)
![](https://www.investors.com/wp-content/uploads/2019/07/stock-Hubspot-05-company.jpg)
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.jpeg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2021/11/shutterstock_1667119063.png)
![](https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_0.png?width=1200&height=800&fit=crop)
Breaking Down Neurocrine Biosciences: 8 Analysts Share Their Views
February 08, 2024
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image.jpeg?width=1200&height=800&fit=crop)
![](https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU33.jpg)
![](https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU2.jpg)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU6.jpg)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU5.jpg)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU6.jpg)
![](/next-assets/images/schema-image-default.png)
Earnings Outlook For Neurocrine Biosciences
February 06, 2024
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.png?width=1200&height=800&fit=crop)
Unveiling 13 Analyst Insights On Neurocrine Biosciences
January 23, 2024
Via Benzinga
![](https://www.investors.com/wp-content/uploads/2017/05/IRU6.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/02/12/bz_pharma_briefs_0.jpeg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU33.jpg)
![](https://www.investors.com/wp-content/uploads/2024/01/Stock-colorfullightbulb-generatedai-01-adobe.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.